^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 positive

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1d
    Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial. (PubMed, BMC Cancer)
    This trial has been approved by the Institutional Review Board (IRB) and began patient enrollment in January 2024. The trial will provide insights into the safety and effectiveness of a novel combinatorial therapy for BCBM.
    P1 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)
    1d
    AI and Tomosynthesis for Breast Cancer Molecular Subtyping: A step toward precision medicine. (PubMed, Annu Int Conf IEEE Eng Med Biol Soc)
    While challenges remain in distinguishing Luminal B2, the use of BT imaging and AI demonstrates promise for refining molecular subtype assessment and improving clinical decision-making.Clinical Relevance-This study demonstrates that AI-driven analysis of digital breast tomosynthesis can capture tumor and microenvironment characteristics, providing valuable insights into disease staging and progression. By leveraging comprehensive imaging data rather than limited biopsy samples, this approach has the potential to improve non-invasive molecular subtyping, aiding personalized treatment decisions while reducing reliance on invasive procedures.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    1d
    Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial. (PubMed, Clin Cancer Res)
    Combining palbociclib, trastuzumab, and ET was safe and improved significantly PFS, compared to TPC in previously treated HER2-positive, PAM50 luminal A/B ABC patients.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Ibrance (palbociclib) • Kadcyla (ado-trastuzumab emtansine)
    2d
    Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response. (PubMed, Front Oncol)
    The efficacy of NAT regimens containing trastuzumab plus pertuzumab (HP) and trastuzumab plus pyrotinib (HPy) was compared. Both HP and HPy combined with chemotherapy can be considered as optional NAT regimens for HER2-positive BC. The nomogram incorporating common clinical indicators provides a basis for clinicians to predict NAT efficacy at an earlier stage.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)
    2d
    Molecular subtype-driven disparities in intraoperative touch imprint cytology accuracy for sentinel lymph node assessment in clinically node-positive breast cancer treated with neoadjuvant chemotherapy. (PubMed, Eur J Med Res)
    Collectively, our study demonstrates that ITPC exhibits a robust accuracy for detecting SLN metastases in cN + breast cancer patients treated with NAC. The findings support the implementation of molecular subtype-specific SLN management: ITPC alone may be adequate for HER2-positive and TNBC tumors; for hormone receptor-positive (Luminal) subtypes, ITPC may need to be combined with molecular/immunohistochemical analysis.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative
    2d
    Complete response following trastuzumab-deruxtecan in a man with HER2-overexpressing metastatic, poorly differentiated scrotal carcinoma. (PubMed, Oncologist)
    The treatment resulted in a complete response, with a tolerable side effect profile and ongoing treatment-free survival. Our case adds to the literature suggesting clinical benefit of the use of Trastuzumab-deruxtecan in HER2-positive tumors, and underscores the importance of molecular testing for patients with rare tumor subtypes.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    3d
    Delayed Cardiac Dysfunction During Prolonged Use of Trastuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. (PubMed, Breast Cancer (Dove Med Press))
    Elevation of serum BNP could not predict cardiotoxicity. Less frequent LVEF monitoring could be considered during long-term use of trastuzumab.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NPPB (Natriuretic Peptide B)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)
    3d
    Prospective Clinical and Biochemical Evaluation of Breast Cancer in Patient Cohorts. (PubMed, Curr Cancer Drug Targets)
    The results highlight IDC as a predominant BC type, with O+ as the most common blood group among patients. TNBC remains a treatment challenge due to a lack of hormone receptors. Metastases mainly affect the lungs and lymph nodes. Elevated BMI, calcium, and magnesium levels correlate with increased HbA1C, suggesting a diabetic link. Emphasizing personalized treatment, obesity management, and electrolyte monitoring., the present research advocates a holistic approach for improved BC outcomes and suggests fu-ture exploration of metabolic influences.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    3d
    Molecular profiling of the Basal-like intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer. (PubMed, Genome Med)
    ERpHER2n-Basal breast cancer represents a clinically high-risk subgroup whose molecular resemblance to TNBC highlights potential therapeutic opportunities, particularly for immunotherapy and DNA repair-targeting treatments.
    Journal • PARP Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • HRD (Homologous Recombination Deficiency)
    |
    HER-2 positive • ER positive • HER-2 negative • HRD • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    3d
    BIS-Program: Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (clinicaltrials.gov)
    P2, N=33, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=185 --> 33 | Trial completion date: Feb 2026 --> Dec 2024 | Recruiting --> Terminated; Abandon of the partner, ROCHE
    Enrollment change • Trial completion date • Trial termination • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Perjeta (pertuzumab)
    3d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    4d
    A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1, N=123, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2026 --> May 2026 | Trial primary completion date: Dec 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • Actemra IV (tocilizumab) • runimotamab (RG6194)